Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1400||SWOG||A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1400ANCILLARY||SWOG||Ancillary Study to Evaluate Patient and Physician Attitudes; Knowledge; and Expectations Related to Return of Genomic Results in Cancer in the SWOG 1400 (S1400) Clinical Trial||Adult CIRB - Late Phase Emphasis|
|S1403||SWOG||A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced; EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1404||SWOG||A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1406||SWOG||Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|S1416||SWOG||Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1418||SWOG||A Randomized; Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1500||SWOG||A Randomized; Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968]; Crizotinib [NSC #749005]; Savolitinib [NSC #785348]; and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1501||SWOG||Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer; Phase III||Cancer Prevention and Control CIRB||Available to Open|
|S1505||SWOG||A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|